Sanofi India Limited (formerly Aventis Pharma Limited) on Tuesday announced the launch of AllStar, its first indigenously manufactured re-usable insulin pen.
Developed especially for Indian patients by Sanofi’s Medical Device Development team at Frankfurt, AllStar is indicated for use of insulinised patients using Sanofi’s insulin portfolio. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with new features.
Insulin therapy is one of the cornerstones of diabetes management, and its efficacy in early as well as late-stage diabetes is well-established. Yet, the first choice of doctors in India for most diabetics has so far been to attempt sugar control through OADs (Oral Anti-Diabetics), diet control, exercise and lifestyle changes.
One of the key reasons for delaying control through insulin is the resistance and fear in patients, of taking injections daily, particularly self-administering the same, the company said.
AllStar is custom-made for patients in India. It will help improve both insulin initiation and compliance; and bring ease and reassurance to the lives of Indian patients, giving them the convenience of international standards at an affordable price.
Announcing the launch of AllStar, Dr. Shailesh Ayyangar, Managing Director, Sanofi India & Vice President South Asia, Group Sanofi, said, “For almost three years, Sanofi’s scientists worked closely with our team here to develop a device that was ‘made in India, for India’.”
“The launch of AllStar is a significant milestone in Sanofi India’s diabetes growth story, and also underlines the Sanofi Group’s focus on diabetes, emerging markets and our regionalised approach to finding solutions that are adapted to local needs,” he added.
